Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

NCT01918865 ↗

Phase 2 Completed 92 enrolled Ionis Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.

Timeline

Start: 2013-08
Primary completion: 2014-10
Completion: 2015-02

Publications

Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes. Diabetes Care. 2018 Apr;41(4):807-814. doi: 10.2337/dc17-2132. Epub 2018 Feb 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ISIS-PTP1BRx	Antisense oligonucleotide	200 mg	—
Background	Metformin	Small molecule	—	—

Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications